ArticlePharmaceutical research2017
Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use.Biomolecules · 2023Pooled it
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Review
- Review
- In Vitro Assessment ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.EJNMMI radiopharmacy and chemistry · 2024Review
- Therapeutic potential of [European journal of nuclear medicine and molecular imaging · 2024Article
- Synthesis, Characterization, and Therapeutic Efficacy ofPharmaceutics · 2023Article
- Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers.Molecules (Basel, Switzerland) · 2023Article
- Mechanisms of Nanoscale Radiation Enhancement by Metal Nanoparticles: Role of Low Energy Electrons.International journal of molecular sciences · 2023Review
- Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia.Metabolites · 2022Review
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2022Review
- Differential Radiosensitizing Effect of 50 nm Gold Nanoparticles in Two Cancer Cell Lines.Biology · 2022Article
- Review
- Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology.EJNMMI radiopharmacy and chemistry · 2022Review
- Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy.Journal of nanobiotechnology · 2021Article
- Treatment with Radiopharmaceuticals and Radionuclides in Breast Cancer: Current Options.European journal of breast health · 2021Review
- Au@Pt Core-Shell Nanoparticle Bioconjugates for the Therapy of HER2+ Breast Cancer and Hepatocellular Carcinoma. Model Studies on the Applicability ofMolecules (Basel, Switzerland) · 2021Article
- Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy.Frontiers in oncology · 2021Review
- Lipidic Cubic-Phase Nanoparticles (Cubosomes) Loaded with Doxorubicin and Labeled withNanomaterials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the effectiveness of trastuzumab-modified gold nanoparticles (AuNP) labeled with
methodsAuNP (30 nm) were modified with polyethylene glycol (PEG) polymers linked to trastuzumab or to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelators to complex
resultsTrastuzumab-AuNP-
conclusionTrastuzumab-AuNP-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.